Research programme: single-chain anticancer antibodies - Oncobiologics

Drug Profile

Research programme: single-chain anticancer antibodies - Oncobiologics

Alternative Names: ONS-1010; ONS-1015; ONS-1020; ONS-1025; ONS-1030; ONS-1035; ONS-2010; sc-Fv bi-specific

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncobiologics
  • Class Bispecific antibodies; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Uterine cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Head-and-neck-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Malignant-melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top